ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,222.68
0.16%
US Tech 100
17,650.00
0.05%
다우존스 지수
39,512.84
0.32%
Bitcoin
61,053.88
0.42%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. BridgeBio Pharma Inc (BBIO)

  7. BridgeBio Pharma Inc (BBIO) 뉴스

BBIO BridgeBio Pharma Inc

29.10
0.37 (1.29%)
11 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
BridgeBio Pharma Inc BBIO 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
0.37 1.29% 29.10 07:23:24
개장가 저가 고가 종가 전일 종가
28.92 27.895 29.16 29.10 28.73
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
02/05/202420:30GLOBEBridgeBio Pharma Reports First Quarter 2024 Financial..
02/05/202420:00GLOBEBridgeBio launches BridgeBio Oncology Therapeutics (BBOT)..
10/04/202420:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
08/04/202402:15GLOBEBridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR)..
20/03/202420:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
07/03/202407:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/03/202407:13EDGAR2Form 8-K - Current report
06/03/202413:53GLOBEBridgeBio Pharma Announces Pricing of Public Offering of..
05/03/202407:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/03/202406:17GLOBEBridgeBio Pharma Announces Proposed Public Offering of..
04/03/202421:00EDGAR2Form 8-K - Current report
04/03/202416:30GLOBEBridgeBio Pharma and Bayer Announce European Licensing..
23/02/202406:27EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/02/202421:31EDGAR2Form 8-K - Current report
22/02/202421:30GLOBEBridgeBio Pharma Reports Fourth Quarter and Full Year 2023..
22/02/202406:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/02/202406:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/02/202406:06EDGAR2Form 144 - Report of proposed sale of securities
14/02/202406:05EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
14/02/202406:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/02/202421:34GLOBEBridgeBio Pharma and Kyowa Kirin Announce Partnership with..
06/02/202421:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
05/02/202421:30GLOBEBridgeBio Pharma Announces U.S. Food and Drug Administration..
02/02/202421:00GLOBEBridgeBio Pharma Shares Positive Results of Single-Arm Phase..
30/01/202421:00PRNUSInvitae Partners with BridgeBio Pharma to Harness Genetic..
19/01/202406:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/01/202421:30EDGAR2Form 8-K - Current report
18/01/202421:00GLOBEBridgeBio Pharma Secures up to $1.25 Billion of Capital from..
17/01/202406:04EDGAR2Form 144 - Report of proposed sale of securities
11/01/202407:15GLOBEBridgeBio Pharma Announces Publication of Positive Results..
10/01/202421:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
09/01/202407:14EDGAR2Form 8-K - Current report
06/01/202406:06EDGAR2Form S-8 - Securities to be offered to employees in employee..
04/01/202406:30GLOBEBridgeBio Pharma to Participate in the J.P. Morgan..
03/01/202421:30GLOBEBridgeBio announces FDA clearance of IND application for..
20/12/202306:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202306:13EDGAR2Form 144 - Report of proposed sale of securities
13/12/202321:30GLOBEBridgeBio Announces First Child Dosed in PROPEL 3, its Phase..
08/12/202321:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
05/12/202322:52DJNBridgeBio Seeks FDA Approval of Acoramidis in Transthyretin..
05/12/202321:44GLOBEBridgeBio Pharma Announces Submission of New Drug..
21/11/202306:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/11/202306:27EDGAR2Form 144 - Report of proposed sale of securities
18/11/202306:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202306:03EDGAR2Form 144 - Report of proposed sale of securities
13/11/202300:30GLOBEBridgeBio Pharma Presents Additional Clinical Outcomes Data..
09/11/202321:30GLOBEBridgeBio Pharma to Present Additional Data from the Phase 3..
08/11/202321:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
03/11/202305:59EDGAR2Form S-3ASR - Automatic shelf registration statement of..
02/11/202320:31EDGAR2Form 8-K - Current report

최근 히스토리

NASDAQ
BBIO
BridgeBio Pharma
GATE
HORDUSDT
HORD Token
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유